TRANSLATIONAL STEM CELL STUDIES

Consensus Guidance for Banking and Supply of Human Embryonic Stem Cell Lines for Research Purposes

The International Stem Cell Banking Initiative

Background and Scope

In just a few years hundreds of human embryonic stem cell (hESC) lines have been established in laboratories around the world and many programmes of research initiated to investigate their properties and broad ranging potential in therapy and for other research applications, such as developmental biology, toxicology and drug discovery. This work is being performed with a variety of cell lines using a variety of culture conditions; a situation that makes standardisation between projects and publications very difficult and could prevent the identification of cells that have undergone permanent deleterious changes. Clearly the consequence of using such cells would be wasted time and resources but, more seriously, the generation of erroneous data in the literature which could both confuse and delay scientific progress in this area. Thus ensuring that cell lines used in this dynamic field have the correct identity and characteristics is critical to the delivery of effective and efficient research of acceptable quality.

Many centres now distribute hESC lines around the world but the preparation and testing of cell stocks released to other researchers is generally based on local 'norms' and naturally varies from centre to centre. The challenge of preparing satisfactory cells for use in research work has been recognised and guidance has been developed by international groups on good cell culture practice [1] and cell banking [2, 3]. In response to the lack of formal coordination between the active distributing centres from different countries the International Stem Cell Forum, a group of national and international stem cell research funding bodies, has funded this initiative, the International Stem Cell Banking Initiative (ISCBI), to establish a dialogue between the distribution centres to develop a consensus on the principles of best practice for the banking, testing and distribution of hESC [4, 5] cells. Due to local conditions and procedures some distributors of hESCs may not address all items as described in this guidance. However, where this occurs the distributor in question must be able to justify their position. The first meeting of this group was held at the Jackson Laboratory (Maine, USA) in October 2007 and this guidance document represents the first output from the ISCBI. The document has been prepared from the perspective of hESC culture but, in many respects, is broadly applicable to all human stem cell lines including induced pluripotent stem cell lines.

Informed Consent, Traceability and Governance

General Principles

Banks must comply with their own domestic laws and regulations (see ISCF website) and should also verify compatibility with international ethical principles such as the guidance established by the International Society for Stem Cell Research (ISSCR) and other relevant bodies.

Banks should obtain documentation pertinent to the provenance of the cell line, which includes evidence – and

The complete list of contributors to the International Stem Cell Banking Initiative are listed at the end of the paper. Correspondance should be directed to G Stacey at Glyn.Stacey@nibsc.hpa.org.uk

The International Stem Cell Banking Initiative
Blanche Lane,
Ridge, Herts, UK
e-mail: Glyn.Stacey@nibsc.hpa.org.uk

scope- of the donor's free and voluntary informed consent, traceability measures and of the safeguards necessary to ensure the privacy of donors and donor information. Ideally, this should also enable traceability to the original donor but this should be coded, or otherwise anonymised, such that the bank cannot access details of donors directly, but through a formal mechanism via another independent party or organisation.

A review of international ethical safeguards and further information from the ISCF Ethics Working Party and others can be found at http://stemcellforum.org/.

Procedures to Assist Ethical Operation

Each bank should have an independent and transparent governance structure which reviews the ethical provenance of cell lines accepted by the bank consistent with 'General Principles' above. Depositors of cells should demonstrate that they have met all legal and ethical requirements associated with procurement of tissue and derivation of the cell lines. The depositor of the cell line should provide information that enables the banks governance structure to determine whether these conditions are broadly consistent with the bank's national regulation. Moreover, banks should have in place a mechanism to maintain awareness of changes in regulation.

Governance of Cell Supply

Only ethically approved projects should receive cells from the bank. This should be determined before the Materials Transfer Agreement (MTA) is signed in which this constraint is indicated (see Shipment of Cells and 'Information for Users'). To avoid distribution for unethical purposes, the users should be prohibited from third party distribution without prior permission from the bank.

Banks should also consider ethical responsibility in the case of discovery of infectious or genetic disease in a cell line according to domestic laws and ethical norms (see ISCF website for sources of information).

The Cell Banking Process

Procurement of Cell Lines

The conditions of consent for the use of donated cells and tissue for research purposes should be subjected to appropriate scrutiny. Accordingly, traceability should be established for each stem cell line as well as for the informed consent from the original donor of cells used to derive the cell line (see 'Informed Consent', 'Traceability and Governance').

The establishment of archive material is important for future reference and useful samples include cells from the original donor and fixed cells (e.g. "Guthrie cards", 'FTA' cards (Whatman)) or DNA from early passages of the cell line to enable confirmation of genetic identity of cell banks. In addition, vials of the cryopreserved cell line supplied by depositors can be held unopened in case the banked cells are later found to have altered characteristics or contamination.

Fundamental information from depositor of a cell line in the bank should include: cell identity, contamination status, viral testing, passage level, mycoplasma testing and key cell antigen and molecular marker tests. Details of the testing recommended and cell bank specifications and release criteria are given in 'Informed Consent', 'Traceability and Governance', 'Cell Characterisation' and 'Release Criteria for Cell Banks'.

Cell Banking Procedures and Documentation

Banks should be accredited, designated, authorised or licensed by an appropriate authority for the purpose of their activities. They should also comply with domestic laws, guidelines and international norms for the banking and use of hESC lines. Banks should be subject to formal mechanisms for legal, ethical and scientific oversight in order to maintain public trust.

Operation of a formal and documented Master Cell Bank and Working Cell Bank system [1] is strongly recommended to enable supply of reproducible cells at the same passage level over long time periods. Cells would normally be supplied from the 'Working Cell Bank' which may be called the 'Distribution Cell Bank'. In addition, the bank must establish a quarantine procedure for newly acquired cell lines in order to avoid spread of any contamination they may contain.

For all processes involving culture or manipulation of cells the risk of microbiological contamination from raw materials should be evaluated (see 'Microbiological Testing'). The use of antibiotics in culture media may be necessary for derivation of cell lines, but is not recommended for preparing cell banks and other experimental work, with the notable exception of cell clones expressing 'marker' genes that are maintained under antibiotic selection (this is important to avoid the longer term problems that can be associated with suppressed contamination).

Documentation of banking procedures is vital for the bank to be able to demonstrate that it has worked in compliance with appropriate regulatory standards and to address and 'troubleshoot' complaints from recipients and internal failures in quality control. Documentation should include all information provided with deposited cell lines, consistently recorded data from quality control and characterisation and standard operating procedures for all key processes and protocols. Materials and procedures used to prepare each cell bank should also be traceable. All data available on a particular cell

line should be collated or referenced in a cell line master file that will provide a central source of information on that cell line and the stocks established in the bank.

Frozen stocks of a particular cell line should not be stored in a single location. In order to avoid the risk of complete loss of cell lines, the bank should provide back-up storage facilities at a second site that would enable regeneration of the original stocks. Off-site stored material should be held under conditions equivalent to those at the bank site. The bank should operate an inventory management system and procedures should be in place to ensure the accuracy and reliability of labeling and location records. The loss of cell lines due to substandard maintenance of cold storage would have a significant impact on the credibility of the bank, and auditing the bank storage system is an important factor in assuring secure long-term storage of material and is strongly recommended. As a minimum, an internal audit process should be employed to carry out periodic checks on the reliability and robustness of maintenance procedures for stored materials. Where formal standards apply for medical use, testing or other purposes, a formal independent audit process may be required for all cell culture and testing procedures.

Cell Bank Quality Control

The past experience of other culture collections distributing cell lines has identified that an important principle of quality control (QC) for cell lines is that it enables the bank to state, subject to certain qualification, that the cells are what the bank 'says' they are and that microbial contamination was not detected. In order to achieve this for human stem cell lines and indeed any stored cells, it is vital to establish key criteria for the quality control and characterisation of the cells and these are addressed in detail in 'Microbiological Testing', 'Cell Characterisation' and 'Release Criteria for Cell Banks'. Clearly qualification of cell lines, through appropriate and rigorous quality control, is critical and should be a mandatory function for a bank. It should also be remembered that QC is just one part of overall quality assurance procedures for the bank, which should also cover aspects such as correct function of facilities and equipment, and staff training. In some applications of cell lines, where specific quality standards apply, the bank will need to understand and possibly comply with such standards, examples of which include standards from the international standards organisation (www.iso.org/):

- ISO9001:2000 a general quality management standard for provision of services and products
- ISO17025 for laboratory testing and monitoring including the use of cell lines for 'batch release' testing of medical products

- ISO13485 for diagnostic testing procedures including the use of cells or cell-derived reference materials
- ISO34 Guide for preparation of reference materials

Other international guidance is also available for general cell culture (e.g. reference 1), safety testing [6] and establishment of cell lines for the manufacture of medicinal products [7, 8].

The Process of Releasing Cell Banks

Historically researchers have often sourced lines from unqualified sources in their colleagues' laboratories and this practice unfortunately promoted the widespread use of cross-contaminated and mycoplasma infected cell lines [9, 10]. Banks should actively work towards establishing expedient procedures to promote prompt access to cell lines to minimise the need for 'colleague-supply' routes. As part of this process banks need to work towards low cost simple testing regimes that can also be used by recipients of stem cell lines.

For each cell bank there should be an associated 'specification' which describes the key characteristics of each line. The 'specification' should meet the requirements for the cell to be "suitable for use" i.e. for use in stem cell research work. The specification must be matched by the quality control and characterisation data for each bank of cells before they can be released (for details see 'Release Criteria for Cell Banks').

It is recommended that with current culture methods banks should avoid shipment of growing cultures. Pooling multiple straws or vials from the same frozen stock may be necessary for a recipient to successfully recover a culture. However, banks should aim to provide sufficient 'viable' cells in a single container to enable appropriately trained staff to recover a representative culture.

Culture manuals should be available from the bank, ideally 'on-line', along with key standard operating procedures. Release of cells to researchers should be accompanied with advice and training; recipients should either have evidence of past training or training should be provided as part of cell supply.

It is recommended that the bank should make stocks of especially critical reagents, such as feeder cells, available to recipients to get their work started efficiently. Banks should advise recipients to produce a cryopreserved stock of each stem cell line on supplied feeders before switching to local feeder cells.

A complaints procedure should be in place which should be responsive to avoid frustration for recipients and enhance reputation of the bank. The bank should also have a clear replacement policy for cultures which fail to thrive in the hands of recipients. All complaints should be reviewed to assess the effectiveness of the corrective actions taken and to look for opportunities to improve service.

Technical support is important to users of the bank and should be provided.

Microbiological Testing

Risk Evaluation

Microbial contamination can change the characteristics of cells without causing obvious cytopathic effects and the unwitting use of such cultures could not only affect the quality of research data (for example viral infection may be non-lethal to cells and alter their biological performance), but could also expose researchers to infectious agents. In principle, stem cell lines should be free of any microbial contamination as far as can be reasonably determined by the bank. Cells with established 'stable' infection with specific agents may have useful research applications but, should be handled separately from 'clean' cultures with no evidence of infection.

It is vital that the bank has a rationale for the tests performed. Sterility and mycoplasma testing are microbiological tests that should be performed on all cell cultures used in the bank; these are covered in technical aspects of release procedures. The bank's drivers for safety testing will normally be to protect bank staff and users and to deal with liability that may be associated with the supply of cells to research workers. In addition to microbiological risks there is a formal but low risk of tumor formation following subcutaneous inoculation of a tumorigenic cell line as a result of accidents in the use of 'sharps' such as hypodermic needles. Whilst this risk would appear to be very small, the bank should aim to minimize it and take special care with immuno-compromised bank staff. Furthermore, where human or animal cells have been subjected to transfer in animals, it should be remembered that there is potential for transfer of animal virus from the host.

The bank should be aware of donor testing results relating to individual cell lines, but these should not be used alone. Caution should be taken in the use of donor testing as the reliability of test data may vary and contamination can occur after cell isolation. In addition, 'positive' viral testing in donors does not necessarily exclude the use of cells for cell line derivation e.g. hCMV. Where reagents of biological origin are used there may be a risk of contamination (see Table 1 for examples). Banks should consider obtaining risk-evaluated products that have been appropriately tested for microbial contamination. The infectious risk represented by different cell growth media products can be difficult to assess, but can be evaluated in the light of a number of factors outlined below.

- Issues relating to source animals. Species and tissue of origin and the geographical location, husbandry and health/microbiological screening of source animals and raw product harvesting procedures. In particular it is important to evaluate the risks from potential microbial contamination of serum. This will require careful documentation of batches used and their origin.
- Product manufacture. Nature of the processing, purification and formulation methods, including assessment of any added materials and the capacity of different steps in this process for reducing the level of any potential contaminants.
- Nature, effectiveness and reliability of any sterilisation or disinfection steps. Many proteins, such as growth factors, will not survive methods of sterilisation such as autoclaving or destructive irradiation. However, processes such as 'Pasteurisation', filtration, chemical treatment and lower level irradiation can be quite effective at reducing the viable microbial load in cell culture products.
- Testing performed on the product. Viral testing of animal derived products will be most appropriate when no sterilisation process can be used. Care should be taken to assess viral testing to ensure that appropriate methods were employed that have been demonstrated to give defined and acceptable levels of sensitivity and specificity and were performed by a qualified or accredited laboratory with appropriate experience in the tests performed.

It should be remembered that no current testing regime can guarantee absolute absence of microbial contamination and, therefore, cells should be considered to remain potentially infectious even where comprehensive testing has been carried out.

Microbiological Test Procedures

Documentation of genetically modified components and pathogenic agents (e.g. recombinant cells, contaminated cell lines, control organisms) is important and may be a legal requirement (see relevant national rules).

Virus testing should be performed on early archive or master stocks that will be used for establishment of any future distribution stocks. It is recommended that banks should test human cell lines for serious and primarily blood born pathogens e.g. HepB, HepC, HIV, HTLV I/II, EBV and hCMV. This may be expanded to other viruses that may contaminate cells from the human reproductive tract (e.g. HPV, HSV, HHVs) depending on local policy, incidence of disease amongst donors and other risk factors identified for the individual cell line. The bank should have a documented procedure for dealing with positive microbiological results arising during testing.

Currently no recommendation can be made on tests for prions and agents of transmissible spongiform encephalopathies (TSEs), due to lack of validated sensitive methods and lack of information specific to contamination of stem cells. However, banks should carry out periodic reviews of developments in microbiological testing and, consider appropriate collaborative projects, to ensure that they maintain current best practice in testing regimes.

Microbiological testing should be performed using qualified methods and banks should hold information on sensitivity, specificity, robustness and other validation work that indicates fitness for the purpose of testing cell lines specifically. Viral screening may be mandatory under certain regulatory environments.

Endogenous retroviruses could arise in any cell culture and are known to be expressed at the RNA level in numerous cancer-derived cell lines and in murine cells. Retrovirus-like sequences provide normal functional elements in some key processes in human biology including the development of the placenta. However, the potential hazards arising from interaction of these sequences with other retroviruses (e.g. contaminants, deliberate infection of cells) to form novel viruses, should be considered.

Microbiological Issues for Supply of Cells

The bank must assure the capability of cell line recipients to handle potentially contaminated cells safely. The bank should also provide advice to recipients on safe handling that can be incorporated in local rules.

Banks should provide recipients with a statement listing and qualifying the testing performed on cells supplied including indication of the 'analyte' (i.e. test material) used.

The bank should have a policy on dealing with new microbiological data that may arise after cell banks have been released. This may include notification of all recipients of potentially affected cells (see ISCF website for information on national and local rules applicable to national banks).

Cell Characterisation

General Principles

Banks are considered to have a primary role to play in meticulous characterization of stem cell lines available for research. They must also confirm consistency for each cell line between deposited cells, master stocks and cells for distribution ('The Cell Banking Process', 'Banking Procedures').

A critical feature regarding the pluripotency of hESC cell lines is that they should at least form 'teratomas' in immune-compromised mice. The definition for nomenclature of these tumors has been a matter of recent debate but the conclusion recently adopted by *Nature Biotechnology* [11], following expert consultation, is as follows:

'.... Nature Biotechnology will adopt the term 'teratocarcinoma' to describe malignant tumors comprising both somatic tissues and undifferentiated malignant stem cells, identifiable as EC cells. .... We will apply the term 'teratoma' only to tumors composed of normal, 'benign' somatic tissue and their immature (fetal) precursors derived from more than one of the three embryonic germ layers (ectoderm, mesoderm and endoderm). Teratomas comprising nonproliferating somatic tissue may be further labeled as 'benign', 'mature' or 'fully differentiated'. Teratomas composed of immature, proliferating fetal-like tissues may be labeled 'immature'?.

It is strongly recommended that distributors of stem cell lines should adopt this terminology.

Morphology continues to be an important criterion in stem cell research and banks should provide representative images of undifferentiated and differentiated cells (NB under defined culture conditions and post seed/subculture time) for users to compare with their own cultures. Ideally the bank should also make images available of typical immuno-cytochemistry and examples of undesirable features such as differentiation.

Table 1 List of biological reagents used in stem cell derivation and culture and associated microbiological hazards

Reagent	Source	Potential Contaminants
Fetal calf serum	Bovine fetuses	Bovine viruses e.g. bovine viral diarrohea virus, bovine polyoma virus (numerous serum free media available but may still contain materials of animal origin)
Trypsin	Porcine pancreas	Porcine viruses (risk of contamination reduced by using recombinant trypsin produced in microorganisms or plants[a])
Bacterial enzymes such as Collagenase	Bacterial cultures of *Clostridium spp.*	Spores and organisms from the original culture[a]
Growth factors	Animal/human tissues and cells	Viral contamination depending on the species of origin[a]

[a] **NB** Altering the source of a biological reagent using recombinant DNA approaches may eliminate certain hazards but if the new source of material is still of biological in origin (e.g. recombinant organisms) then there may still be materials used in its preparation that represent a risk of contamination, however, this will generally not be a significant issue for materials used for research purposes.

There are certain key cell markers for the characterisation of stem cell lines that should be used by the bank, and these are described in Phenotype below.

Methods and Measurements

Phenotype

A standardised international study [12] of hES cell phenotypic markers confirmed for a large group of hESC cell lines that a typical surface marker profile for these cells is SSEA-1 (negative or very low), SSEA-3 'positive', SSEA-4 'positive', TRA-1-60 'positive' and TRA- 1-81 'positive' (NB, SSEA-3 & -4 have the potential to reveal different patterns for a very small number of individual donors i.e. 1%). In the same study microfluidic arrays for Q-RT PCR revealed that expression of six genes could be recommended for confirmation of the hESC phenotype: Nanog, Oct 4, DNMT 3B, TDGF, GABRB3, GDF3. These markers were found to be strongly correlated in stem cells. It is important to note that other cell types may express these markers but it is the overall profile of expression, not expression of individual markers, that is key. Flow cytometry (FC) is the central methodology for canonical markers of stem cells identified above. Immunocytochemistry is also valuable to provide additional data on morphology and localization of antigen. Multiple fluorochromes are useful for flow cytometry to evaluate coexpression, etc. Measurement of expression by FC should be recorded and available to bank users along with the method of FC data collection and the FC instrument used. Care should be taken in how data is collected and expressed and this should be clear to bank users. In particular, the bank should carefully and unambiguously report the meaning of data referring to "% positive cells". Banks should use appropriate controls in FC analysis (fixed cell preparations are under development in the International Stem Cell initiative www. stemcellforum.org.uk). Bank SOPs for such phenotypic analyses should be made available to users.

RNA expression profiling gives desirable additional supporting data on associated gene groups but for critical interpretation such data should be confirmed at the protein level.

In all analytical work on feeder cell dependent stem cells, care should be taken to exclude the feeder cells from cell samples to avoid interference in data on stem cell lines. In addition, it is useful to use a preparation of pure feeder cells as a control.

Genotype

Each genotyping technique gives a different type of data and it is important that the bank understands and reports the advantages and limitations of the methods it uses.

Karyology by Giemsa-banding (G-banding) should be performed as a routine genotyping technique. However, it should be recognized that some diploid cells may carry undetected genetic alterations; and techniques such as "spectral karyotyping" (SKY), comparative genome hybridization (CGH) microarray and multiple single nucleotide polymorphism (SNP) analysis can provide useful additional information. However, comparative data from different methods will need to be collated from different centres over time. It is important to remember that the number of cells analysed can be critical for sensitivity of detecting abnormal clones and the bank should make such details available to users.

G-banding analysis can detect the appearance of chromosomally abnormal clones, however, the number of metaphase spreads analysed is critical to the sensitivity of their detection. Where karyologically abnormal cells are found, repeat testing is recommended to confirm the findings (see below). Abnormal sub-clones of stem cell lines should be renamed and information and cells made available as they may be useful in genetic research or for high throughput screening methods.

The following guidance indicates the minimum work necessary for the cytogenetic analysis of hESC cell cultures. Standard G-band analysis of prepared cell metaphase 'spreads' should include a chromosome count for 20 metaphases and banding patterns analysed in a minimum of 8 metaphases. It is to be expected that occasional abnormal karyotypes will be observed in hESC cell line analyses and these may appear to be present in all cells (i.e. clonal) or in a minority of cells (nonclonal). Chromosomal abnormalities that appear to be of clonal origin should be confirmed by repeat analysis. Abnormalities seen in single cells (i.e. presumed non-clonal) may result from a technical artifact, but may be due to a developing clonal abnormality or low level mosaicism [13, 14]. Chromosomal analysis of a repeat sample from the culture may be helpful in determining the basis of apparent anomalies. Standard terms and methodology for G-banding analysis of hESC cells adopted in this guidance are given in Table 2. These were developed as a consensus between the standards used in the USA and the Association of Clinical Cytogeneticists General Best Practice Guidelines (2007) [15] available on that organisation's website (see website list). New international guidance on definitions and standards for cytogenetic analysis are given in ref [16].

Pluripotency

The bank should provide some form of evidence for the potential of each stem cell line to produce cells representative of the three germ layers that ultimately give rise to all cells of the body. The 'gold standard' for this pluripotency is considered to be the ability of stem cells should at least form teratomas in SCID mice. This should be performed on

each cell line at least once in its history and the bank should make all efforts to ensure that this characteristic is not lost by *in vitro* manipulation in the bank.

Assays of cell features deemed to be subject to variation in culture should be carried out by the bank. If certain hESC lines are found that do not form teratomas, they may also have value for research into pluripotency. It is considered important that teratoma formation tests should be applied to all cells that may be used for clinical purposes.

Alternative methods are available for the determination of potential pluripotency including formation and characterisation of embryoid bodies and *in vitro* induced differentiation. Standardisation of any pluripotency assay will prove challenging. This is an area which is under development and banks should keep up to date on current technical progress. In the future it will be extremely helpful if the methods used are sufficiently accessible that they can be reproduced in all user laboratories.

Cell Line Stability and Epigenetics

In order to avoid any subtle changes in cell characteristics, it is recommended that for each cell line banks use the depositor's methodology, at least up to the first cryopreserved stock of cells or Master Cell Bank. Banks should monitor cultures for adaptation to *in vitro* conditions (e.g. changes in growth rate, cloning efficiency) and attempt to minimise the risk of changes in stem cell cultures by:

- Minimising culture passages (a Master- and Working cell bank system is key to this; see 'The Cell Banking Process') and being aware of culture methods that could induce change
- Publishing subculturing methods for recipients to use
- Passaging cells beyond typical levels used by recipients of cell lines and requalify cells at these time points
- Making recommendations to recipients not to use cells beyond a specified passage level from a characterised cell bank

It is important to record actual passage number and to notify recipients of the passage level of cells provided. Population doublings may be difficult to estimate with current protocols, however, this is considered a more accurate and useful measure of replicative 'age' of a cell culture and it would be highly desirable to have such data available from the bank. Banks should keep up to date with current technical developments in this area to ensure that bank procedures reflect current best practice.

Investigation of epigenetic variation occurring in stem cell lines is at an early stage and more data is needed before routine tests can be recommended for stem cell banks. However, banks should keep up to date on current scientific and technical developments in this area.

Release Criteria for Cell Banks

General Principles

Bank cultures should be representative of the originally deposited material i.e. quality control and characterisation data should show no evidence that the banking process has altered the cell line in comparison to the cells provided by the depositor.

The bank should provide assurance that cell lines released have no detected microbial contamination and, that as far as can be determined, they are 'monoseptic' i.e. a single uncontaminated viable cell line. This assurance can be provided through a combination of cell-identity testing and microbiological isolation methods but should be qualified based on the types of organisms that might be detected by the testing regime used.

Identity testing is critical to demonstrating that the cell line is unique (i.e. not switched with, or cross-contaminated by, another cell line). Banks should share identity data to avoid spread of cross-contaminated cultures, but should take care in general with dissemination of genetic information that may be donor-specific i.e. could have a significant influence on the healthcare of the donors or lead to donors being identified.

'Sterility' tests from antibiotic-free cultures should be performed on cell banks to provide evidence for absence of bacterial and fungal contamination. Banks should seek to extend these tests to cover fastidious organisms, including mycoplasma and certain bacteria that may contaminate cell cultures but are not detected by standard sterility test methods for bacteria and fungi.

Mycoplasma species are a frequent cause of contamination in cell culture and can be introduced from a variety of sources including bovine serum, feeder cells, animal-derived raw materials (e.g., trypsin) or humans. Mycoplasma species are one of the greatest risks for potential contamination of mammalian cell lines with several studies estimating rates of contamination as high as 15-30% in cell lines that are shared between research labs [17–19]. Although over 20 different mycoplasmas have been isolated from cell lines, the vast majority of contaminations are typically due to eight species: *Mycoplasma hyorhinis* (porcine trypsin), *M. arginini* (bovine serum), *M. fermentans* (human), *Acholeplasma laidlawii*, *M. hominus* (human), *M. orale* (human), *M. bovis* (bovine) and *M. pulmonis* (murine). Due to their small size, filtration is not always effective at removing mycoplasma from cell culture

Table 2 The karyological analysis of hESC lines: recommended terms, standard method and procedures for investigation of abnormal results and reporting of data

Standard G-band Analysis	A minimum of 8 metaphases analysed
	20 metaphases counted
Procedure for investigation of clonal abnormal findings	Clonal chromosome abnormalities should be confirmed in a second later passage culture, to allow further interpretation of their significance (see Genotype)
Procedure for investigation of abnormalities observed in single cells	Single cell abnormalities (e.g. aneuploidy, structural rearrangements) will require further investigation in some cases to exclude mosaicism, depending on the chromosome involved.
	Aeuploidy of chromosomes 1, 8, 12, 14, 17, 20 and X (incl. unbalanced rearrangements) — A minimum of 30 G-banded cells counted from initial culture. Examine 100 interphases using FISH with appropriate probe of a follow up later passage culture and 30 G-banded cells.
	Other aneuploidy and structural abnormalities — A minimum of 30 G-banded cells counted from initial culture.
Minimum quality score	ISCN 400 band level is the minimum level of G-banding analysis necessary, although effort should be made to analyse cells of ISCN 500 band level and above.
	The method used to score the banding is at the laboratory's discretion. An example of a banding scoring system can be found in the UK's Association of Clinical Cytogenetics Best Practice Guidelines (2007) (ref. 15).
	www.cytogenetics.org.uk/prof_standards/acc_general_bp_mar2007_1.01.pdf
Substandard analysis	If analysis at the ISCN 400 band level cannot be achieved, the analysis can proceed as normal but should be reported with the caveat that it is a "substandard analysis" and may need to be repeated.
Report	The result reported should include:
	–The karyotype designation using current correct ISCN nomenclature 2009 (ref. 16), where practicable.
	–The types of analysis used (e.g. karyotype, FISH, CGH, special types of banding etc).
	–The average banding level achieved. Single cells with aneuploidy or structural abnormalities involving chromosomes 1, 8, 12, 14, 17, 20 or X (this list is evolving) should be reported, even after extended analysis, as it is necessary to analyse a second, later passage culture to fully interpret the abnormality
Definitions (Adapted from ACC General Best Practice Guidelines, 2007) (ref. 15)	**Analyse** – to count a metaphase and compare every chromosome, band for band, with its homologue and to verify the banding pattern of the X and Y-chromosomes in male karyotypes.
	Count – To enumerate the total number of chromosomes in any given metaphase in such a way that gross structural abnormalities would be identified, or in FISH analysis to enumerate the number of signals in an interphase nucleus.
	Score – To check for the presence or absence of abnormalities in a cell or metaphase without full analysis.
	Clone – A cell population originally derived from a single cell.
	Such cells will have an identical chromosome constitution. A clone is said to exist if three cells have lost the same chromosome, or two cells contain the same extra or structurally rearranged chromosome.

media and reagents. In addition, mycoplasma contamination of cell cultures is often difficult to detect since gross changes in culture (e.g., turbidity) are not commonly observed. Mycoplasma contamination, however, can result in significant changes in cell metabolism and growth characteristics and can have a dramatic effect on cell phenotype and chromosome structure. Due to the high frequency of mycoplasma contamination, good cell banking practices should include measures for early detection and preventing the spread of contamination.

Cells should not be released if they are known to carry a viral hazard to laboratory workers or a virus that may influence research data from the culture in question. It is possible that persistently infected cells would have significant value in research but these would have to be handled separately in appropriate facilities and the infection notified to recipients.

In addition to tests for certain viral pathogens (see 'Microbiological Testing'), banks should also consider inclusion of testing for other contaminants prevalent in the local environment, media supply and donor groups.

Technical aspects of release procedures

Each bank should establish a clear set of release criteria that should apply to each bank of cells. a recommended minimum set of criteria for release of hESC cell banks is given in Table 3.

A similar test regime should be established for feeder cell banks based on a minimum requirement for sterility testing, mycoplasma testing and viability as described for hESCs (Table 3). In addition, identity testing and appropriate virological testing (see 'Microbiological Testing') should be carried out for human feeder cells. Mouse embryonic feeder

Table 3 Proposed testing for hESC master cell banks[a]

Test	Specification	Examples of test methods	Typical test result pass specification	Release criteria
Identity	Matches parent cell line	Short Tandem Repeat (STR) Testing Human Leukocyte Antigen (HLA) Testing	Shares all alleles of parent cell line	Passes test result specification
Bacteria/fungi	No contamination detected	Inoculation of microbiological culture media to detect growth of bacteria and fungi[b]	No culturable bacterial or fungal organisms detected[d]	Passes test result specification
Mycoplasma	No contamination detected	Direct culture in broth and agar and indirect test using indicator culture/ DNA stain[b]	No culturable mycoplasma detected[d]	Passes test result specification
Karyotype	Report karyotype from a specified number of metaphase analyses (see Methods and measurements)	Perform G-band analysis of 20 metaphase spreads (see Table 2). Further analysis may be performed using FISH.	Single karyotype in all cells analysed. No alternative karyotypes at or above 5% of metaphase 'spreads' in the cell preparation (see 'Methods and Measurements')	Passes test result specification
Post-Thaw Recovery	Viable colonies recovered (quantified efficiency of recovery of each bank/lot should be given)	Test for the ability to recover viable hESC colonies	Colonies recovered that are representative of the original cell line as demonstrated in other quality control and characterization data[e]	Passes test result specification
Pluripotency	Report data available	Formation of teratomas in immune-deficient (SCID) mice (see 'Pluripotency' of this guidance). Also formation of embryoid bodies and in vitro 'directed' differentiation.	Data presented	(see footnote [f])
Growth Characteristics	Report value	Growth characteristics under standard cell culture conditions. Determine doubling time.	Growth rate estimate presented	–
Cell Antigen Expression	High proportion of cells (typically >70%) positive for each marker	Flow cytyometry for a arrange of hESC markers (e.g.SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, Oct-4) and SSEA-1 negative..	Data presented	–
Cell Gene Expression	Report data available	Gene expression profiling using DNA microarray or Q-PCR analysis. Analyze for expression of core hESC genes as well as markers of differentiated cell types.	Data presented if available	–
Genetic stability	Report data available	Analysis of multiple Single Nucleotide Polymorphisms. Comparative Genome Hybridization by DNA microarray methodology.	Data presented if available	–

[a] Testing on stocks other than the Master cell bank may not need to be so extensive but should be defined by the bank

[b] Tests consistent with pharmacopoeial methods are recommended

[c] Cell differentiation capacity can be determined during characterization studies performed on distribution lots/banks. These studies should be performed on cells passaged beyond the distribution lot passage level e.g. 20 passages

[d] Use appropriate controls to assist in validation of result, sensitivity determination and false negatives due to inhibition of assays. Sensitivity should be known and validated for hESC samples in the hands of the testing laboratory

[e] The bank should establish a justified specification that may be dependent on the needs of customers. This is a developing area in which banks should maintain knowledge of current developments and best practice. Coordination between banks is vital to continue to improve viability of preserved cells supplied to bank users

[f] 'Pluripotency' should be a release criterion for stem cell lines which the bank asserts to be potentially pluripotent. Where this is included in release criteria the cell bank report should be based on a defined protocol for the methodology and data evaluation

cells should be obtained from animal colonies with an appropriate standard of husbandry compliant with national and/or international standards, including colony screening for common murine pathogens. Mouse antibody production tests can be used for virus detection in mouse feeder cells and it is also recommended to prepare large homogenous stocks of these cells to promote consistency and economy. The significance of potential murine virus contamination of human stem cells should also be born in mind when introducing them into animals especially SCID mouse colonies.

Table 4 Mycoplasma detection methods

Technique/Test Method	Comments
Selective broth and agar subculture/industry standard methods are published in national pharmacopoeia	Generally considered the most sensitive method for detecting culturable *Mycoplasma* and *Acholeplasma* species.
	Long incubation periods are required with final results not available for several weeks.
DNA stain (Hoechst or DAPI) of inoculated Vero cells (industry standard methods are published in national pharmacopoeia).	Can isolate mycoplasma strains that do not grow in broth/agar method.
	Simple to carry out providing a high magnification uv-epiflourescent microscope is available.
	Results available within a few days give good sensitivity but generally not considered to provide the level of sensitivity obtained using culture methods.
	Rapid direct staining can be performed, but may suffer from cell and bacterial artefacts leading to ambiguous results.
PCR/ variety of methods based on amplification of mycoplasma DNA e.g., 16S rRNA, 23S rRNA, rpoB, ITS. Representative references include [20–24].	Detects non-culturable organisms
	Useful for screening cultures due to easy sample preparation and rapid production of test results (within hours)
	May be very sensitive but some methods can lead to false positives (important to validate the specific method used for sensitivity and specificity)
	PCR assays are also subject to limited sensitivity due to small sample volume and inhibition of the PCR reaction by sample components. Sensitivity can be addressed by use of diluted DNA controls and sample spiking with positive controls ([23]).
Detection of mycoplasma specific enzymes/examples of commercially available kits are given	MycoTect (Invitrogen): detects a wide range of mycyoplasma species based on levels of the mycoplasma-specific enzyme adenosine phosphorylase.
	MycoAlert (Cambrex): reported to be capable of detecting down to 20 cfu/mL of several mycoplasma species.

Mycoplasma tests should be performed on newly deposited cells under quarantine and all cell banks established. Several different assay methods are currently available for mycoplasma testing, including culture methods, PCR-based assays and detection methods based on the presence of mycoplasma-specific metabolic enzymes. Mycoplasma testing of distribution cells is typically conducted using either culture or PCR-based assays since these methods can provide broad coverage of *Mycoplasma* and *Acholeplasma* species. A brief overview of these methods is provided in Table 4. The chosen test methods should be validated for their specificity and sensitivity for testing cell lines. For the testing cell banks, a combination of methods used to give high sensitivity and detection of non-culturable strains is recommended.

Identity testing should be performed on samples of early stage material (early passage cell DNA preserved either frozen or on storage cards e.g. 'Guthrie cards', 'FTA' cards (Whatman)) and all cell banks established (see 'The Cell Banking Process'). It is recommended to use systems with core common alleles represented in forensic work and examples from commercially available STR kits are given in Table 5. Publication of STR profiles

of recently isolated human stem cell lines may present ethical issues in some countries. However, it is recommended that banks should share such data for the purpose of identifying cross-contaminated cell lines and preventing their release. Failure to do this could have a serious long term effect on the validity of research data performed with such lines.

"Viability" is a difficult parameter to define - frozen vials or straws should enable recovery and expansion of a 'representative' culture within a certain time (see Table 3). The bank should formally qualify the viability method it uses to test thawed vials from frozen stocks intended for distribution. Viability test data can be used as a release test but should not be used as an absolute indicator of the 'quality' of a stem cell bank. This can only be demonstrated through successful completion of a range of quality control and characterisation tests.

The composition of cell types should be evaluated for test samples from each bank and should include percentage of cells positive for markers and the level of apparently differentiated cells (see 'Cell Characterisation'). The functional properties of cells should also be addressed and the key property of pluripotency is dealt with in 'Cell Characterisation'.

Table 5 Examples of STR genetic alleles represented in commercially available kits

Gene locus name	Applied biosystems				Promega
	Cofiler (USA)	ProfilerPlus (USA)	Identifiler (UK)	SGM + (UK)	Power Plex 16 (UK, USA)
Amelogenin	+	+	+	+	+
D3S1358	+	+	+	+	+
D16S539	+	–	+	+	+
TH01	+	–	+	+	+
CSF1PO	–	–	+	–	+
TPOX	+	–	+	–	+
D7S820	+	+	+	–	+
D13S317	–	+	+	–	+
D21S11	–	+	+	+	+
D18S51	–	+	+	+	+
D8S1179	–	+	+	+	+
FGA	–	+	+	+	+
vWA	–	+	+	+	+
D5S818	–	+	+	–	+
D2S1338	–	–	+	+	–
D19S433	–	–	+	+	–
Penta D	–	–	–	–	+
Penta E	–	–	–	–	+

Key: + , indicates alleles for which each kit has primer sets

Supply Issues

The bank should remind recipients of lines that the testing performed on each cell bank may not detect microbial contamination below the level of detection or organisms not covered in the testing regime and thus recipients should be advised to handle the cells as if potentially infectious.

Shipment of Cells and 'Information for Users'

General Principles

"Instructions For Use"(IFU) and/or Standard Operational Procedures for culture and preservation should be provided to bank users. The IFU should typically contain information prescribing general culture and preservation methods and what procedures the cells have been qualified or consented for (e.g. "*in vitro* research only", "not for generation of gametes", "not for reproductive cloning").

Lot numbers for the cells shipped should be provided to users that are traceable to the 'lot' or cell bank. It is also recommended that data on the Master Cell Bank is made available by the bank. Banks should supply, with the cells, test results obtained from that specific stock of cells (i.e. a Certificate of Analysis for each bank

listing data including quality control and characterisation). It is also desirable for these to be available from the bank website. A statement or materials safety data sheet on hazards associated with the cells should be supplied with cell shipments. Terms and Conditions or a warranty should be provided which qualifies cell potential and characteristics based on testing performed by the bank.

Information Available to Users of the Bank

Such information should include: standard operating procedures (culture, preservation etc.) and characterisation data from the depositor for each cell line in the bank. Each bank should provide a statement on policy for the quality and sourcing of certain raw materials subject to national or international restrictions (e.g. serum). It would also be desirable for data generated on cell lines supplied by each bank to be made available to assist future users of the bank.

Ethical issues may be particularly important for bank users and each bank should provide information to facilitate efficient selection of suitable lines. Relevant information would include date of preservation of tissue, date of attempted 'derivation' (for hESCs, this is usually considered to be the date the inner cell mass was isolated or plated *in vitro*); whether fresh or frozen embryos used;

whether payment was made for the donation of embryo/tissue; whether the embryo was created for research; the existence of fully informed consent obtained from the donor for use of the original tissue for research; and any associated constraints on the use of the derived line. Information should also be available on the derivation procedure, as well as seminal and key publications for each cell line.

Materials Transfer Agreements (MTAs)

Banks should work within national guidelines and laws on ownership and patenting of biological materials (see the World intellectual property organisation website www.wipo.int/ for general information and for information on patent office contacts in the 184 WIPO member states see www.wipo.int/members/en/).

A common MTA would not be practicable for all banks; however, biological resource organisations have identified key generic elements that should be included (e.g. European Culture Collection Organisation www.eccosite.org/) and there are other national examples that could be considered as templates (e.g. National Cancer Institute – see also links to national banks on the ISCF web site to obtain MTAs from suppliers of stem cell lines).

Transportation

Technical Issues

Vials and straws shipped should be from a homogenous distribution bank of cells (see 'The Cell Banking Process', 'Banking Procedures') and contain sufficient cells to readily recover a culture (see 'Release Criteria for Cell Banks'). The method of transport should be appropriate for the method of preservation and validated by the bank. Typically, cryopreserved vials (i.e. preserved by a slow cooling method) can be shipped on "dry-ice" (solid carbon dioxide) and 'vitrified' materials should be shipped in the vapour phase of liquid nitrogen (i.e. in 'dry-shippers'). In the international distribution of mouse embryos, test vials (or 'dummy' straws) have proven helpful for recipients to test their thawing process.

Preservation methods are developing and improved methods are needed to assist in stable storage and shipment and it is important that banks maintain awareness of current developments in preservation science and technology.

Administrative Procedures

Banks should have a planned and documented shipment process to identify recipient contacts (i.e. a detailed local contact name/tel. no. to receive cells as well as the shipment

address), shipment, delivery dates and shipment tracking information from the courier.

For each shipment the bank should check all local import regulations with the recipient. Helpful information is available from the World Federation of Culture Collections on import regulations http://www.wfcc.org - see also the ISCF stem cell banking webpages for links to different national import/export regulations. Before dispatching cells the bank should also check the necessary international packing and labeling requirements for national and international shipment (see www.iata.com).

Preference should be given to use of shipping agents that can refresh 'dry-ice' or liquid nitrogen and the chosen method of shipment (insulated box of 'dry-ice' or nitrogen 'dry-shipper') and required storage temperature on receipt should be communicated to the recipient laboratory.

References

1. Coecke, S., Balls, M., Bowe, G., Davis, J., Gstraunthaler, G., Hartung, T., et al. (2005). Second ECVAM task force on Good Cell Culture practice. Guidance on good cell culture practice: a report of the second ECVAM task force on good cell culture practice. *Alternatives to Laboratory Animals, 33*, 261–287.
2. ISBER. (2007). Best practices for repositories I: collection, storage, and retrieval of human biological materials for research. *Cell Preservation Technology, 3*, 5–48.
3. OECD (2007) Best Practice Guidelines for Biological Resource Centres; OECD, Paris. http://www.oecd.org/document/50/0,3343, en_2649_201185_1911986_1_1_ 1_1,00.html
4. Healy, L. E., Ludwig, T. E., & Choo, A. (2008). International banking: checks, deposits and withdrawals. *Cell Stem Cell, 2*(4), 305–306.
5. Crook, J. M., Hei, D., & Stacey, G. (2010). International Stem Cell Banking Initiative (ISCBI): Raising standards to bank on. In Vitro Cell Dev Biol-Animal, (in press).
6. OECD Advisory Document of the Working Group on Good Laboratory practice: the application of the principles of GLP to in vitro studies. OECD series on principles of Good laboratory practice and Compliance monitoring 2004; Number 14 (ENV/JM/MONO(2004)26), OECD, Paris. http://www.olis.oecd.org/olis/2004doc.nsf/linkTo/nT00008FEE/$FIlE/JT00174939.PdF
7. International Conference on Harmonisation. ICH Topic Q 5 D Quality of Biotechnological Products: derivation and characterisation of cell substrates used for production of Biotechnological/Biological Products (CPMP/ICH/294/95), 1998; ICH Technical Coordination, European Medicines Evaluation Agency, London.
8. WHO (Expert Committee on Biological Standardization and Executive Board) requirements for the use of animal Cells as in vitro substrates for the production of biologicals (requirements for Biological substances no. 50). 1998; WHO technical report series no. 878; World Health Organization, Geneva.

9. Chatterjee, R. (2007). Cell biology: cases of mistaken identity. *Science, 315*, 928–931.

10. NIH (2007) Notice regarding authentication of cultured cell lines, NOTod-08-017, Nov 28, NiH. http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-017.html

11. Editorial (2007). *Nature Biotechnology*, 1211–1212.

12. International Stem Cell Initiative: Adewumi, O., Aflatoonian, B., Ahrlundrichter, L, Amit, M., Andrews, P. W., Beighton, G., et al. (2007). Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. *Nature Biotechnology, 25*, 803–816.

13. Sikkema-Raddatz, B., Castedo, B., & Meerman, G. T. (1997). Probability tables for exclusion of mosaicism in prenatal diagnosis. *Prenatal Diagnosis, 17*, 115–118.

14. Hook, E. B. (1977). Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use. *American Journal of Human Genetics, 29*, 94–97.

15. Association of Clinical Cytogenetics General Best Practice Guidelines. 2007; v10.01, ACC Professional Standards Committee.

16. An International System for Human Cytogenetic Nomenclature (2009) In L. G. Shaffer, M. L. Slovak, L. J. Campbell (Eds.), *Cytogenetic and Genome Research*. Switzerland: Karger.

17. Bolske, G. (1988). Survey of mycoplasma infections in cell cultures and a comparison of detection methods. *Zbl Bakt Nug, A269*, 331–340.

18. Rottem, S., & Naot, Y. (1998). Subversion and exploitation of host cells by mycoplasma. *Trends in Microbiology, 6*, 436–440.

19. Timenetsky, J., Santos, L. M., Buzinhani, M., & Mettifogo, E. (2006). Detection of multiple mycoplasma infection in cell cultures by PCR. *Brazilian Journal of Medical and Biological Research, 39*, 907–914.

20. Eldering, J. A., Felton, C., Veilleux, C. A., & Potts, B. J. (2004). Development of a PCR method for mycoplasma testing of Chinese hamster ovary cell cultures used in the manufacture of recombinant therapeutic proteins. *Biologicals, 32*, 183–193.

21. van Kuppeveld, F. J. M., Johansson, K.-E., Galama, J. M. D., Kissing, J., Bolske, G., van der Logt, J. T. M., et al. (1994). Detection of mycoplasma contamination in cell cultures by a mycoplasma group-specific PCR. *Applied and Environmental Microbiology, 60*, 149–152.

22. Sung, H., Kang, S. H., Bae, Y. J., Hong, J. T., Chung, Y. B., Lee, C.-K., et al. (2006). PCR-Based Detection of mycoplasma species. *Journal of Microbiology, 44*, 42–49.

23. Uphoff, C. C., & Drexler, H. G. (2005). Detection of mycoplasma contaminations. *Methods in Molecular Biology, 290*, 13–23.

24. Kong, H., Volokhov, D. V., George, J., Ikonomi, P., Chandler, D., Anderson, C., et al. (2007). Application of cell culture enrichment for improving the sensitivity of mycoplasma detection methods based on nucleic acid amplification technology (NAT). *Applied Microbiology and Biotechnology, 77*, 223–232.

Websites

www.stemcellforum.org

www.cytogenetics.org.uk/prof_standards/acc_general_bp_mar2007_1.01.pdf

www.iata.com

www.wfcc.org

www.wipo.int/members/en

The International Stem Cell Banking Initiative contributors

Peter W. Andrews[1], Javard Arias-Diaz[2], Jonathan Auerbach[3], Manuel Alvarez[4], Lars Ahrlund-Richter[5], Duncan Baker[6], Nissim Benvenisty[7], Dalit Ben-Josef[8], Guillaume Blin[9], Lodovica Borghese[10], Joeri Borstlap[11]. Kevin Bruce[12], Oliver Brüstle[13], Robin Buckle[14], Carine Camby[16], Andre Choo[17], Wannhsin Chen[18], Daniel Collins[12], Alan Colman[19],Catriona Crombie[14], Jeremy Crook[20], Ray Cypess[21], Paul De Sousa[12], Jyotsna Dhawan[22], Luc Douay[23], Petr Dvorak[24], Timothy Dyke[25], Lena Eriksson[26], Meri Firpo[27], Claire Fitzgerald[28], Clive Glover[29], Paul Gokhale[2], Michele Greene[30], Hye-Yeong Ha[31], Ales Hampl[24, 32], Lyn Healy [15], Derek Hei[34], Frida Holm[5], Outi Hovatta[5], Charles Hunt[15], Shiaw-Min Hwang[35], Maneesha Inamdar[36], Rosario Isasi[37], Joseph Itskovitz-Eldor[38], Nancy Jessie[39], Dong-Wook Kim[40], Rosemarie Kirzner[21], Sorapop Kiatpongsan[41], Barbara Knowles[42], Hung-Chih Kuo[43], Mary Laughlin[44], Neta Lavon[45], Tenneille Ludwig[46], Majlinda Lakov[47], Dong-Ryul Lee[48], John Macauley[49], Ronald McKay[50], Phillipe Menasche[51], Pablo Menendez[52], Anna Michalska[53], Maria Mileikovskaia[54], Stephen Minger[55], Gyan Mishra[56], Jennifer Moody[29], Karen Montgomery[57], Clive Morris[25], Christine Mummery[58], Andras Nagy[59], Yukio Nakamura[60], Norio Nakatsuji[61], Shin-Ichi Nishikawa[62], Steve Oh[17], Sun Kyung Oh[63], Patricia Olson[64], Timo Otonkoski[65], Milind Patole[56], Hyun-Sook Park[66], Xuetao Pei[67], Martin Pera[68], Michel Puceat[9], Kristiina Rajala[69], Benjamin Reubinoff[70], Allan Robins[71], Heather Rooke[72], Victor Rumayor[2], Heli Scotman[69], Jon Sherlock[73], Carlos Simon[74], Douglas Sipp[62], Rebecca Skinner[53], David Smith[75], Glyn Stacey[15], Sonia Stefanovic[9], Raimund Strehl[76], Robert Taft[49], Tsuneo Takahashi[77], Sohel Talib[64], Stefanie Terstegge[13], Rodney Turner[73], Timo Tuuri[65], John Yu[81], Peter Zandstra[4], Augustin Zapata[2], Fanyi Zeng[78], Qi Zhou[79], Shelly Tannenbaum[80].

Project coordinator and corresponding author: Glyn N Stacey, National Institute for Biological Standards and Control (NIBSC), South Mimms, Hertfordshire, UK (Glyn.Stacey@nibsc.hpa.org.uk).

Contributors Affiliations

[1]Centre for Stem Cell Biology, University of Sheffield, UK. [2]Instituto de Salud Carlos III, Madrid, Spain. [3]GlobalStem, Inc. Rockville, U.S.A. [4]University of Toronto, Canada. [5]Karolinska Institute, Stockholm, Sweden. [6]National Health Service/University of Sheffield, UK. [7]Hebrew University of Jerusalem, Institute of Life Sciences, Jerusalem, Israel. [8]Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, [9]INSERM, Evry, France. [10]University of Bonn, Bonn, Germany. [11]Charité-University Medicine Berlin, Berlin, Germany. [12]Roslin Cells, Edinburgh, Scotland UK. [13]Institute of Reconstructive Neurobiology, University of Bonn, Germany. [14]Medical Research Council, London, UK. [15]National Institute for Biological Standards and Control, South Mimms, UK. [16]formerly Agence de la Biomedicine, Paris, France. [17]Bioprocessing Technology Institute, Singapore. [18]Industrial Technology Research Institute, Hsinchu, Taiwan. [19]A-Star (formerly ESI), Biopolis, Singapore. [20]O'Brien Institute, Melbourne, Australia (formerly of, A-Star, Singapore). [21]American Type Culture Collection, Mannassas, Virginia, USA. [22]Centre for Cellular and Molecular Biology, Hyderabad, India. [23]Universitè Pierre et Marie Curie, Paris, France. [24]Masaryk University, Brno, Czech Republic. [25]National Health and Medical Research Council, Canberra, Australia. [26]formerly University of York, York, UK, [27]Stem Cell Institute and Schulze Diabetes Institute, University of Minnesota, Minneapolis, Minnesota, USA. [28]Harvard University, Howard Hughes Medical Institute, Boston, USA. [29]Stem Cell technologies, Canada. [30]formerly Millipore. [31]Korean Stem Cell Research Center & Yonsei University College of Medicine, Seoul, Korea. [32]Institute of Experimental Medicine, Brno, Czech Republic. [33]Waisman Center, University of Wisconsin-Madison, Wisconsin, USA. [35]Bioresource Collection and Research Center, Taipei, Taiwan.

[36]Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India. [37]Universite de Montreal, Montreal, Canada (ISCF Ethics Working Party representative). [38]Rambam Medical Centre and Technion Institute of technology, Haifa, Isreael, [39]R&D Systems. [40]Stem Cell Research Center Yonsei University College of Medicine, Seoul, Korea. [41]Chulalongkorn University, Bangkok, Thailand, [42]Institute of Medical Biology, A*Star, Singapore [43]Genomics Research Center/Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan. [44]Case Medical Center/ISCT, Cleveland University Hospital, Cleveland (International Society for Cell Therapy representative), [45]Institute of Life Sciences, The Hebrew University of Jerusalem, Israel. The International Stem Cell Institute, Cedars-Sinai Medical Center, Los Angeles, USA. [46]Wicell Research Institute, Wisconsin. [47]Newcastle Centre for Life, Newcastle, UK. [48]Cha Hospital, Seoul, South Korea. [49]The Jackson Laboratory, Bar Harbor, USA. [50]National institutes of Health, Washington, USA. [51]Hospital European, Georges Pompidou, Paris, France [52]Andalusian Stem Cell Bank, Granada, Spain.[53]Australian Stem Cell Centre, Melbourne, Australia. [54]Mount Sinai Hospital, Ontario, Canada.[55]Kings College London, UK. [56]National Centre for Cell Science, Pune, India. [57]WiCell Research Institute, Madison, USA. [58]Leiden University Medical Center, Leiden, The Netherlands. [59]Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada. [60]Riken BioResource Center, Ibaraki, Japan. [61]Kyoto University, Kyoto, Japan. [62]Riken Center for Developmental Biology, Kobe, Japan. [63]IRMP, MRC, Seoul National University College of Medicine, Seoul, South Korea, [64]California Institute for Regenerative Medicine, San Francisco, USA. [65]University of Helsinki, Helsinki, Finland. [66]MCTT Inc., Seoul, South Korea. [67]Beijing Institute for Transfusion, Beijing, China. [68]University of Southern California, Los Angeles, USA. [69]Regea - Institute for Regenerative Medicine, University of Tampere, Tampere University Hospital, Tampere, Finland. [70]Hadassah University Medical Organization, Jerusalem, Israel. [71]Novocell Inc., Athens, USA. [72]International Society for Stem Cell Research, Deerfield, USA. [73]Applied Biosystems part of Life Technologies, Foster, USA. [74]University of Valencia, Valencia, Spain. [75]CABI Europe-UK, Egham, UK. [76]Cellartis AB, Goteborg, Sweden. [77]University of Tokyo, Tokyo, Japan. [78]Shanghai JiaoTong University, Shanghai Institute of Medical Genetics, Shanghai, China. [79]Chinese Academy of Sciences, Beijing, China. [80]Hebrew University Medical Center, Jerusalem, Israel. [81]Genomics Research Center/Institute of Cellular and Organismic Biology, Academia Sinica, Tapei, Taiwan.